Kura Oncology, Inc.

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial. For additional information, please visit our website at www.kuraoncology.com.